Rate Video

iwMyeloma 2015 | Emerging monoclonal antibodies for the treatment of multiple myeloma

Rafael Fonseca • 11 Apr 2015

Multiple Myeloma Antibodies Elotuzumab

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses novel monoclonal antibodies (mAbs) for the treatment of multiple myeloma. Anti-CD38 mAbs and elotuzumab are showing promising activity in clinical development.

Patient-specific targeted therapy in myeloma: t(11;14) and venetoclax

Rafael Fonseca • 15 Oct 2021

When is the use of MRD appropriate?

Rafael Fonseca • 1 Jun 2018

MRD in multiple myeloma: determining response

Rafael Fonseca • 1 Jun 2018

Is precision medicine a bust in myeloma?

Dirk Hose et al. • 7 Sep 2018

Related Videos

PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma

Adam Sperling • 13 Jun 2022

Dual-targeting BCMA/CD19 CAR-T therapy in patients with R/R MM

Juan Du • 13 Jun 2022

The association between prior exposure to lenalidomide and TP53-mutated AML/MDS

Adam Sperling • 13 Jun 2022

Updates in immunotherapy for multiple myeloma: BiTEs & novel targets

Adam Sperling • 13 Jun 2022